Product Code: RP-ID-10086073 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10086073
Market Overview:
Global Sleep Apnea Devices Market - By Diagnostic Devices, By Therapeutic Devices, By End User, By Region, By Country (2018 Edition): Forecast to 2030- - By Diagnostic Devices (Polysomnography, Respiratory Polygraphs, Pulse Oximeter, Actigraphy), By Therapeutic Devices (CPAP, APAP, Bi-PAP, ASV, Facial Interfaces, Oral Appliances),By Region (N. America, Europe, APAC, ROW), By Country 2022-2030
"The global market for sleep apnea devices in 2021 is anticipated to be USD 4 billion and it is expected to expand at a compound annual growth rate (CAGR) of 7% between 2022 and 2030. Sleep apnea is a sleep disorder characterized by irregular breathing, which provides insufficient oxygen supply to the brain. According to a study published by the American Sleep Association in 2020, an estimated 50 to 70 million people in the United States suffer from some form of sleep disorder. In addition, according to data from the Canadian Respiratory Journal in 2014, approximately 5.4 million adults in Canada have been diagnosed with sleep apnea or have an increased risk of OSA. According to a study conducted by ResMed in 2018, about 175 million people in Europe suffer from sleep apnea.
The prevalence of sleep apnea in the elderly is very high, and it has not been fully diagnosed due to factors such as people;s lack of knowledge and non-specific manifestations of the disease. Due to the increase in life expectancy, the elderly population continues to increase, which is expected to lead to an increase in the prevalence of sleep disorders. For example, according to data from the World Health Organization, in 2018, the world;s population of 60 years and over is expected to reach 2 billion by 2050. In addition, the world;s elderly population (over 60 years old) will double from 12% to 22%. In addition, OSA is a common disease among the elderly, and by 2020, approximately 13% to 32% of people over 65 will be affected .
The increase in the elderly population is expected to promote the adoption of these devices, because this population is more prone to sleep apnea. In addition, the prevalence of sleep apnea in the elderly is increasing because the comorbidities associated with sleep apnea are high in the elderly. In addition, patients with obesity and hypertension are more prone to sleep apnea.
According to an analysis by the Centers for Disease Control and Prevention, the prevalence of obesity in the United States from 2015 to 2016 was 39.8%, representing nearly 93.3 million adults. According to estimates by the World Health Organization in 2019, more than 50% of men and women living in Europe are overweight. The average obesity rate in the region is 23.3%. Therefore, the number of people affected may increase during the forecast period.
In addition, according to the Mayo Clinic, men are 2-3 times more likely to suffer from sleep apnea than women. In 2017, the number of men in the United States was approximately 161 million, and this number is growing rapidly. Therefore, the prevalence is expected to increase in the next few years. It is expected that the presence of a large number of patients will increase the demand for CPAP and other therapeutic equipment. Diseases associated with sleep apnea include hypertension, obesity, diabetes, and cardiovascular disease. OSA is characterized by airway collapse, leading to frequent episodes of apnea and hypopnea, which in turn leads to irregular breathing and adverse effects on the body; for example, it has been found that about 73% of patients diagnosed with stable heart failure episodes suffer from sleep Respiratory disorders (SRD). In addition, it is also one of the main causes of high blood pressure. The severity of RRT is directly proportional to the risk of developing hypertension.
PRODUCT TYPE INFORMATION:
The therapeutic device market segment occupies a dominant position, with the largest revenue share in 2020, at 80%. Treatment devices include positive airway pressure devices, oral devices, nasal devices, and chin straps.
Increasing awareness of these diseases, increasing availability of technologically advanced equipment, increasing local government initiatives, and patient adherence to supportive treatments, these factors are expected to provide device manufacturers with lucrative opportunities. In turn, this is expected to drive growth in the field of therapeutic devices during the forecast period.
REGIONAL INFORMATION:
In 2020, North America dominates the sleep apnea device market with the largest revenue share of 48%. The increasing prevalence of respiratory diseases has led to one form or another of sleep disorders, which has promoted the development of the market. In addition, the increasing awareness of sleep apnea, the large number of patients, and the presence of international manufacturers are factors that are expected to strengthen market share in the region. For example, major players such as ResMed, Philips Respironics, and Somnetics International, Inc. have established strong influence in the region and established strong distribution channels to promote the supply of their products. In addition, the number of treatment tests conducted in this region to confirm the presence of sleep apnea is rapidly increasing because many people worry about health risks from this condition; however, in the Asia-Pacific region, the market is expected to be significant during the forecast period. increase.
The increase in the elderly population and the increasing prevalence of lifestyle-related diseases are key factors driving the development of the Asia-Pacific market. For example, according to the World Health Organization, chronic respiratory diseases, diabetes, cardiovascular diseases, and cancer are some of the major diseases that cause the most deaths in the region, and according to the 9th edition of the Diabetes Atlas of the Israel Defense Forces, about 87.6 million people live in Southeast Asia The 20-79-year-old age group in the region suffers from diabetes.
The increasing prevalence of chronic diseases is expected to increase the adoption rate of sleep apnea devices in the region. According to an article in PubMed, the prevalence of obstructive sleep apnea in middle-aged Asians ranges from 4.1% to 7.5% in men and 2.1% to 3.2% in women. According to an article by the Asia-Pacific Respiratory Society, in May 2020, the prevalence of mild sleep apnea in Asia-Pacific countries ranges from 7.8% in Hong Kong to 77.2% in Malaysia. The study highlighted the names of four Asian countries in the top 10, with OSA having the highest prevalence. The countries with an estimated OSA prevalence rate of AHI>15 times/hour are China (66 million patients, 8.8% prevalence) and India (29 million, 5.4%).
MAJOR COMPANIES AND MARKET SHARE PROSPECTS:
Intense competition among market participants to expand their geographic presence and strengthen their customer base through various product launches and new product development is an important factor driving the market during the forecast period.
For example, in February 2021, Nyxoah SA, the manufacturer of obstructive sleep apnea (OSA) neurostimulator devices, partnered with Vanderbilt University to create a new neurostimulation solution for the treatment of OSA. Some of the major players in the sleep apnea device market include: ResMedPhillips RespironicsFisher & Paykel Healthcare Limited Curative Medical, Inc. Invacare Corporation Somnetics International, Inc. BMC Medical Co., Ltd. Natus Medical Incorporated SOMNOmedics GmbH Compumedics Limited Itamar Medical Ltd. Nihon Kohden Corporation"
ResMed, Koninklijke Philips, Fisher & Paykel Health, SomnoMed, Compumedics, Itamar Medical Ltd., Whole You, Novasom, Lowenstein Medical, Braebon Medical.
Related Reports
Proof of Quality & Reliability
